Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese

Long-term supplementation with conjugated linoleic acid (CLA) reduces body fat mass (BFM) and increases or maintains lean body mass (LBM). However, the regional effect of CLA was not studied. The study aimed to evaluate the effect of CLA per region and safety in healthy, overweight and obese adults. A total of 118 subjects (BMI: 28–32 kg/m2) were included in a double blind, placebo-controlled trial. Subjects were randomised into two groups supplemented with either 3·4 g/d CLA or placebo for 6 months. CLA significantly decreased BFM at month 3 (Δ = − 0·9 %, P = 0·016) and at month 6 (Δ = − 3·4 %, P = 0·043) compared with placebo. The reduction in fat mass was located mostly in the legs (Δ = − 0·8 kg, P < 0·001), and in women (Δ = − 1·3 kg, P = 0·046) with BMI >30 kg/m2 (Δ = − 1·9 kg, P = 0·011), compared with placebo. The waist–hip ratio decreased significantly (P = 0·043) compared with placebo. LBM increased (Δ = +0·5 kg, P = 0·049) within the CLA group. Bone mineral content was not affected (P = 0·70). All changes were independent of diet and physical exercise. Safety parameters including blood lipids, inflammatory and diabetogenic markers remained within the normal range. Adverse events did not differ between the groups. It is concluded that supplementation with CLA in healthy, overweight and obese adults decreases BFM in specific regions and is well tolerated.

Download Full-text

GH effect on enzyme activity of 11βHSD in abdominal obesity is dependent on treatment duration

Acta Endocrinologica ◽

10.1530/eje.1.02061 ◽

2006 ◽

Vol 154 (1) ◽

pp. 69-74 ◽

Cited By ~ 9

Author(s):

Helga Á Sigurjónsdóttir ◽

Josef Koranyi ◽

Magnus Axelson ◽

Bengt-Åke Bengtsson ◽

Gudmundur Johannsson

Keyword(s):

Insulin Sensitivity ◽

Abdominal Obesity ◽

Fat Mass ◽

Visceral Fat ◽

Controlled Trial ◽

Metabolic Effects ◽

Glucose Disposal ◽

Gh Treatment ◽

Double Blind

Objective: In the past years the interaction of GH and 11βhydroxysteroid dehydrogenase (11βHSD) in the pathogenesis of central obesity has been suggested. Design: We studied the effects of 9 months of GH treatment on 11βHSD activity and its relationship with body composition and insulin sensitivity in 30 men with abdominal obesity, aged 48–66 years, in a randomised, double-blind, placebo-controlled trial. Methods: Urinary steroid profile was used to estimate 11βHSD type 1 and 2 (11βHSD1 and 11βHSD2) activities. Abdominal s.c. and visceral adipose tissues were measured using computed tomography. Glucose disposal rate (GDR) obtained during a euglycaemic–hyperinsulinaemic glucose clamp was used to assess insulin sensitivity. Results: In the GH-treated group the 11βHSD1 activity decreased transiently after 6 weeks (P < 0.01) whereas 11βHSD2 increased after 9 months of treatment (P < 0.05). Between 6 weeks and 9 months, GDR increased and visceral fat mass decreased. Changes in 11βHSD1 correlated with changes in visceral fat mass between baseline and 6 weeks. There were no significant correlations between 11βHSD1 and 11βHSD 2 and changes in GDR. Discussion: The study demonstrates that short- and long-term GH treatment has different effects on 11βHSD1 and 11βHSD2 activity. Moreover, the data do not support that long-term metabolic effects of GH are mediated through its action on 11βHSD.

Download Full-text

A Double-Blind, Randomized-Controlled Trial of a Nutritional Supplement (abs+) Containing Conjugated Linoleic Acid (CLA) and Epigallocatechin-Gallate (EGCG) in Human Weight Loss

Journal of Herbs Spices & Medicinal Plants ◽

10.1300/j044v12n03_05 ◽

2007 ◽

Vol 12 (3) ◽

pp. 67-76 ◽

Cited By ~ 1

Author(s):

A. V. Rao ◽

K. Andrews ◽

A. Logan

Keyword(s):

Weight Loss ◽

Randomized Controlled Trial ◽

Linoleic Acid ◽

Conjugated Linoleic Acid ◽

Controlled Trial ◽

Epigallocatechin Gallate ◽

Nutritional Supplement ◽

Double Blind ◽

Randomized Controlled

Download Full-text

A double-blind, randomized controlled trial (RCT) of L-carnitine and conjugated linoleic acid-based health food with health claims

ANTI-AGING MEDICINE ◽

10.3793/jaam.4.19 ◽

2007 ◽

Vol 4 (1) ◽

pp. 19-27 ◽

Cited By ~ 5

Author(s):

Yoshikazu YONEI ◽

Yoko TAKAHASHI ◽

Miwako WATANABE ◽

Toshito YOSHIOKA

Keyword(s):

Randomized Controlled Trial ◽

Linoleic Acid ◽

Conjugated Linoleic Acid ◽

Controlled Trial ◽

Health Claims ◽

Health Food ◽

Double Blind ◽

Randomized Controlled

Download Full-text

Evaluation of the Antiobesity Effects of an Amino Acid Mixture and Conjugated Linoleic Acid on Exercising Healthy Overweight Humans: A Randomized, Double-blind, Placebo-controlled Trial

Journal of International Medical Research ◽

10.1177/147323001003800311 ◽

2010 ◽

Vol 38 (3) ◽

pp. 844-859 ◽

Cited By ~ 13

Author(s):

T Michishita ◽

S Kobayashi ◽

T Katsuya ◽

T Ogihara ◽

K Kawabuchi

Keyword(s):

Linoleic Acid ◽

Amino Acid ◽

Conjugated Linoleic Acid ◽

Controlled Trial ◽

Amino Acid Mixture ◽

Acid Mixture ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE™ Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0035-1549086 ◽

2015 ◽

Vol 122 (03) ◽

Author(s):

M Blüher ◽

J Wilding ◽

A Astrup ◽

K Fujioka ◽

F Greenway ◽

...

Keyword(s):

Weight Management ◽

Controlled Trial ◽

Efficacy And Safety ◽

Obese Adults ◽

Double Blind

Download Full-text

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Ukrains'kyi Visnyk Psykhonevrolohii ◽

10.36927/2079-0325-v28-is3-2020-5 ◽

2020 ◽

pp. 27-37

Author(s):

Suresh Durgam ◽

Willie Earley ◽

Rui Li ◽

Dayong Li ◽

Kaifeng Lu ◽

...

Keyword(s):

Safety Profile ◽

Relapse Prevention ◽

Controlled Trial ◽

Fixed Dose ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Controlled ◽

Time To Relapse

Cariprazine, a dopamine D3/D2 receptor partial agonist with preference for D3 receptors, has demonstrated efficacy in randomized controlled trials in schizophrenia. This multinational, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy, safety, and tolerability of cariprazine for relapse prevention in adults with schizophrenia; total study duration was up to 97 weeks. Schizophrenia symptoms were treated/stabilized with cariprazine 3—9 mg/d during 20-week open-label treatment consisting of an 8-week, flexible-dose run-in phase and a 12-week fixed-dose stabilization phase. Stable patients who completed open-label treatment could be randomized to continued cariprazine (3, 6, or 9 mg/d) or placebo for double-blind treatment (up to 72 weeks). The primary efficacy parameter was time to relapse (worsening of symptom scores, psychiatric hospitalization, aggressive/violent behavior, or suicidal risk); clinical measures were implemented to ensure safety in case of impending relapse. A total of 264/765 patients completed open-label treatment; 200 eligible patients were randomized to double-blind placebo (n = 99) or cariprazine (n = 101). Time to relapse was significantly longer in cariprazine — versus placebo-treated patients (P = .0010, log-rank test). Relapse occurred in 24.8% of cariprazine- and 47.5% of placebo-treated patients (hazard ratio [95% CI] = 0.45 [0.28, 0.73]). Akathisia (19.2%), insomnia (14.4%), and headache (12.0%) were reported in ≥ 10% of patients during open-label treatment; there were no cariprazine adverse events ≥ 10% during double-blind treatment. Long-term cariprazine treatment was significantly more effective than placebo for relapse prevention in patients with schizophrenia. The long-term safety profile in this study was consistent with the safety profile observed in previous cariprazine clinical trials. ClincalTrials.gov identifier: NCT01412060. Key words: schizophrenia; cariprazine; long-term treatment; relapse prevention; randomized controlled trial; oral antipsychotics

Download Full-text

Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients

Scientific Reports ◽

10.1038/s41598-021-94757-6 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Ting-Ann Wang ◽

Tzy-Haw Wu ◽

Shin-Liang Pan ◽

Hsiu-Hsi Chen ◽

Sherry Yueh-Hsia Chiu

Keyword(s):

Ischemic Stroke ◽

Cerebrovascular Disease ◽

Cox Regression ◽

Controlled Trial ◽

Stroke Recurrence ◽

Long Term Effects ◽

Stroke Patients ◽

Double Blind ◽

Term Survival

AbstractAspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurrence, and long-term survival have not been well elucidated. We aimed to evaluate long-term effect of two kinds of treatment on cerebrovascular death among ischemic stroke patients with or without the recurrence of stroke. Data used in this study were derived from the cohort based on a multicenter randomized double-blind controlled trial during 1992 to 1995 with the enrollment of a total of 466 patients with first-time non-cardioembolic ischemic stroke who were randomly allocated to receive aspirin (n = 222) or nicametate (n = 244). The trial cohort was followed up over time to ascertain the date of recurrence within trial period and death until Sep of 2019. The time-dependent Cox regression model was used to estimate the long-term effects of two treatments on death from cerebrovascular disease with and without recurrence. A total of 49 patients experienced stroke recurrence and 89 cerebrovascular deaths was confirmed. Patients treated with nicametate were more likely, but non statistically significantly, to have recurrence (aHR: 1.73, 95% CI 0.96–3.13) as compared with those treated by aspirin. Nicametate reduced the risk of cerebrovascular death about 37% (aHR: 0.63, 95% CI 0.41–0.97) compared with aspirin. The aspirin group had a lower recurrence rate than the nicametate group even with recurrence after 1–2 years of follow-up of first stroke but the latter had significantly reduced death from cerebrovascular disease for nicametate group, which requires more research to verify.

Download Full-text